Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

被引:142
|
作者
Geng, Ling
Cuneo, Kyle C.
Fu, Allie
Tu, Tianxiang
Atadja, Peter W.
Hallahan, Dennis E.
机构
[1] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[5] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN USA
[6] Novartis Inst Biomed Res Inc, Cambridge, MA USA
关键词
D O I
10.1158/0008-5472.CAN-06-0049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and organization. LBH589 is a novel inhibitor of class I and 11 HDACs. We studied the effect of LBH589 and ionizing radiation (IR) on DNA repair in two human nonsmall cell lung cancer (NSCLC) cell lines (H23 and H460). gamma-H2AX foci present at DNA double-strand breaks (DSBs) were detected in the nuclei following 3 Gy irradiation for up to 6 hours. LBH589 administered before irradiation increased the duration of gamma-H2AX foci beyond 24 hours. Furthermore, radiation alone induced translocation of HDAC4 to the nucleus. In contrast, treatment with LBH589 followed by irradiation resulted in HDAC4 confinement to the cytoplasm, indicating that HDAC inhibition affects the nuclear localization of HDAC4. The findings that LBH589 confines HDAC4 to the cytoplasm and increases the duration of gamma-H2AX foci in irradiated cell lines suggest that HDAC4 participates in DNA damage signaling following IR. Annexin-propidium iodide flow cytometry assays, cell morphology studies, and cleaved caspase-3 Western blot analysis revealed a synergistic effect of LBB589 with IR in inducing apoptosis. Clonogenic survival showed a greater than additive effect when LBH589 was administered before irradiation compared with irradiation alone. In vivo tumor volume studies showed a growth delay of 20 days with combined treatment compared with 4 and 2 days for radiation or LBH589 alone. This study identifies HDAC4 as a biomarker of LBH589 activity and recognizes the ability of LBH589 to sensitize human NSCLC to radiation-induced DNA DSBs.
引用
收藏
页码:11298 / 11304
页数:7
相关论文
共 33 条
  • [22] HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism
    Jian Cui
    Fei Xu
    Wei Bai
    Tiantian Zhao
    Junbo Hong
    Wei Zuo
    Journal of Translational Medicine, 21
  • [23] HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism
    Cui, Jian
    Xu, Fei
    Bai, Wei
    Zhao, Tiantian
    Hong, Junbo
    Zuo, Wei
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [24] Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)
    Ramalingam, S. S.
    Maitland, M.
    Frankel, P.
    Argiris, A. E.
    Koczywas, M.
    Gitlitz, B.
    Espinoza-Delgado, I.
    Vokes, E. E.
    Gandara, D. R.
    Belani, C. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] BIOMARKER ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC; ENCORE-401)
    Jotte, Robert
    Witta, Samir
    Neubauer, Marcus
    Spira, Alexander
    Ruxer, Robert
    Konduri, Kartik
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S607 - S608
  • [26] ANALYSIS OF CROSS-OVER PORTION OF ENCORE-401, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Witta, Samir
    Jotte, Robert
    Neubauer, Marcus
    Spire, Alexander
    Ruxer, Robert
    Konduri, Kartik
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1314 - S1314
  • [27] miR-136 Suppresses the Aggressive Proliferation of Non-Small Cell Lung Cancer Through Restraining Histone Deacetylase 1 (HDAC1) and Phosphorylation of the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (Jak2/STAT3) Pathway
    Yu, Liang
    Zhang, Sheng
    He, Wei
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2022, 12 (04) : 763 - 769
  • [28] A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.
    Fu, Siqing
    Nemunaitis, John J.
    Bessudo, Alberto
    Bauman, Julie E.
    Hamid, Omid
    Witta, Samir E.
    Dy, Grace K.
    Lai, Cheng
    Laliberte, Robert
    Voi, Maurizio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Final Results of a Phase lb Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer
    Voi, M.
    Fu, S.
    Nemunaitis, J.
    Bauman, J.
    Bessudo, A.
    Hamid, O.
    Witta, S.
    Dy, G.
    Lai, C.
    Laliberte, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 181 - 181
  • [30] Insulin-like growth factor-1 attenuates cisplatin-induced γH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer
    Jeon, Jeong Hee
    Kim, Se Kyu
    Kim, Hyung Jung
    Chang, Joon
    Ahn, Chul Min
    Chang, Yoon Soo
    CANCER LETTERS, 2008, 272 (02) : 232 - 241